U.S. Psychiatric & Mental Health Congress

Once identified, adult ADHD may be managed effectively with drugs, psychosocial therapy, experts suggest

Identifying adults with attention-deficit/hyperactivity disorder can be difficult, largely due to popular misconceptions about the illness, but once diagnosed, ADHD can be effectively managed with pharmacologic and nonpharmacologic therapy, according to a pair of experts in the field.

Many adults with ADHD may be ...[more]

Methylphenidate transdermal system shows similar efficacy in male, female children with ADHD, although males may face greater risk of adverse events

The methylphenidate transdermal system (MTS) appears to be similarly effective in male and female children with attention-deficit/hyperactivity disorder, although males may face a higher incidence of adverse events, study data indicate.

Researchers conducted a double-blind, placebo-controlled, parallel-group study in ...[more]

Guanfacine XR effective, safe in long-term treatment of ADHD

Guanfacine extended release (XR) appears to be a safe and effective treatment option for the long-term management of attention-deficit/hyperactivity disorder among children and adolescents, new data show.

Researchers performed an open-label, extension study of up to 24 months. Participants were children aged 6 to 17 years ...[more]

Lisdexamfetamine improves parent-rated measures of ADHD

Treatment with lisdexamfetamine dimesylate appears to significantly improve parent-rated measures of attention-deficit/hyperactivity disorder in children relative to placebo, a post hoc analysis shows.

The secondary analysis was based on data from a double-blind, Phase III trial in which 290 children aged 6 to 12 years ...[more]

Improving outcomes in adolescents, adults with ADHD

Approximately 7% to 8% of children and 4.4% of adults in the United States have attention-deficit/hyperactivity disorder, but only 50% and 10% of those who meet ADHD criteria, respectively, receive treatment, according to Scott Kollins, director of the Duke University ADHD ...[more]

Once identified, adult ADHD may be managed effectively with drugs, psychosocial therapy, experts suggest

Identifying adults with attention-deficit/hyperactivity disorder can be difficult, largely due to popular misconceptions about the illness, but once diagnosed, ADHD can be effectively managed with pharmacologic and nonpharmacologic therapy, according to a pair of experts in the field.

Many adults with ADHD may be ...[more]

Methylphenidate transdermal system shows similar efficacy in male, female children with ADHD, although males may face greater risk of adverse events

The methylphenidate transdermal system (MTS) appears to be similarly effective in male and female children with attention-deficit/hyperactivity disorder, although males may face a higher incidence of adverse events, study data indicate.

Researchers conducted a double-blind, placebo-controlled, parallel-group study in ...[more]

Guanfacine XR effective, safe in long-term treatment of ADHD

Guanfacine extended release (XR) appears to be a safe and effective treatment option for the long-term management of attention-deficit/hyperactivity disorder among children and adolescents, new data show.

Researchers performed an open-label, extension study of up to 24 months. Participants were children aged 6 to 17 years ...[more]

Lisdexamfetamine improves parent-rated measures of ADHD

Treatment with lisdexamfetamine dimesylate appears to significantly improve parent-rated measures of attention-deficit/hyperactivity disorder in children relative to placebo, a post hoc analysis shows.

The secondary analysis was based on data from a double-blind, Phase III trial in which 290 children aged 6 to 12 years ...[more]

OROS methylphenidate safe, effective in adults with ADHD, trial data show

OROS methylphenidate appears safe and effective in adults with attention-deficit/hyperactivity disorder, eliciting dose-dependent improvements in inattention and hyperactivity/impulsivity symptoms, according to findings from the double-blind LAMDA trial.

Researchers randomized 401 adult patients with ADHD and a Conners' ...[more]

Guanfacine XR effective, safe in treating ADHD in children, adolescents, researchers report

Guanfacine extended release (XR) appears effective in treating children and adolescents with attention-deficit/hyperactivity disorder, according to data from a short-term study.

"Many individuals with ADHD do not respond to, cannot tolerate, or prefer alternatives to stimulant treatment," the authors of the study ...[more]

AISRS useful in measuring methylphenidate therapy for adults with ADHD

The Adult Attention-Deficit/Hyperactivity Disorder Investigator Symptom Rating Scale (AISRS) is a sensitive instrument that measures the effect of methylphenidate treatment on the signs and symptoms of ADHD among adults, new data reveal.

The AISRS is a modified version of the ADHD Rating Scale that more accurately ...[more]

Abuse potential with OROS methylphenidate lower than with other methylphenidate formulations

The number of emergency department (ED) reports of abuse with OROS methylphenidate appears to be lower than the number of reports for other formulations of methylphenidate, based on a recent analysis.

Researchers evaluated data from the Drug Abuse Warning Network (DAWN), which is a ...[more]

Comorbidities extremely common in children with ADHD; effective patient management requires treating these illnesses as well, experts report

Comorbidities may be present in as many as two-thirds of children with attention-deficit/hyperactivity disorder, and treating these comorbidities should be considered an integral part of effectively managing these children, a pair of experts in the field indicated.

"Psychiatric comorbidity [in children with ADHD] is ...[more]

Methylphenidate transdermal system linked to deficits in expected growth in children with ADHD

Treatment with the methylphenidate transdermal system (MTS) is associated with small deficits in expected height, weight, and body mass index among children with attention-deficit/hyperactivity disorder; however, new data suggest that these deficits appear to attenuate during time.

"Although stimulant treatment is highly ...[more]

Stimulant dosing in adults with ADHD lower than effective levels

Dosing of stimulants for adults with attention-deficit/hyperactivity disorder appears to fall well below dose ranges that have been shown to be optimally effective in trials of adults with ADHD, according to a new study.

Researchers used service and pharmacy claims from the ...[more]

OROS methylphenidate safe, effective in adults with ADHD, trial data show

OROS methylphenidate appears safe and effective in adults with attention-deficit/hyperactivity disorder, eliciting dose-dependent improvements in inattention and hyperactivity/impulsivity symptoms, according to findings from the double-blind LAMDA trial.

Researchers randomized 401 adult patients with ADHD and a Conners' ...[more]

Guanfacine XR effective, safe in treating ADHD in children, adolescents, researchers report

Guanfacine extended release (XR) appears effective in treating children and adolescents with attention-deficit/hyperactivity disorder, according to data from a short-term study.

"Many individuals with ADHD do not respond to, cannot tolerate, or prefer alternatives to stimulant treatment," the authors of the study ...[more]

AISRS useful in measuring methylphenidate therapy for adults with ADHD

The Adult Attention-Deficit/Hyperactivity Disorder Investigator Symptom Rating Scale (AISRS) is a sensitive instrument that measures the effect of methylphenidate treatment on the signs and symptoms of ADHD among adults, new data reveal.

The AISRS is a modified version of the ADHD Rating Scale that more accurately ...[more]

Abuse potential with OROS methylphenidate lower than with other methylphenidate formulations

The number of emergency department (ED) reports of abuse with OROS methylphenidate appears to be lower than the number of reports for other formulations of methylphenidate, based on a recent analysis.

Researchers evaluated data from the Drug Abuse Warning Network (DAWN), which is a ...[more]

Comorbidities extremely common in children with ADHD; effective patient management requires treating these illnesses as well, experts report

Comorbidities may be present in as many as two-thirds of children with attention-deficit/hyperactivity disorder, and treating these comorbidities should be considered an integral part of effectively managing these children, a pair of experts in the field indicated.

"Psychiatric comorbidity [in children with ADHD] is ...[more]

Methylphenidate transdermal system linked to deficits in expected growth in children with ADHD

Treatment with the methylphenidate transdermal system (MTS) is associated with small deficits in expected height, weight, and body mass index among children with attention-deficit/hyperactivity disorder; however, new data suggest that these deficits appear to attenuate during time.

"Although stimulant treatment is highly ...[more]

Stimulant dosing in adults with ADHD lower than effective levels

Dosing of stimulants for adults with attention-deficit/hyperactivity disorder appears to fall well below dose ranges that have been shown to be optimally effective in trials of adults with ADHD, according to a new study.

Researchers used service and pharmacy claims from the ...[more]